Women's Health

Main Content

Multicenter randomized double-blind, placebo-controlled parallel group study of the efficacy and safety of DigiFab in Antepartum subjects with severe preeclampsia

This study will test the effect and safety of an experimental drug in pregnant women with severe preeclampsia.

  • Principal Investigator: Dr. Rachael Morris

Who can participate

Those eligible to participate in this study include:

  • Pregnant women ages 18 and above at 23 0/7 – 31 6/7 weeks gestation with preeclampsia

For more information

  • Sherrina Dixon
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-7038
  • IRB Number: 2017-0110